



## **Ad hoc announcement pursuant to § 15 WpHG**

**Carl Zeiss Meditec AG achieves revenue growth of approximately 9% in first half year 2015/16**

**Jena, 4 April 2016:** Carl Zeiss Meditec (ISIN: DE0005313704) has achieved revenue of approximately EUR 542 million in the first half year 2015/16, based on preliminary data. This corresponds to a growth rate of around 9% over the previous year's value of EUR 498 million. Currency-adjusted revenue growth amounted to approximately 5.5%.

From today's point of view, the company expects operating profit (EBIT) and earnings per share (EPS) to also rise above the previous year's period.

The half year report 2015/16 will be published on 11 May 2016.

### **Contact for investors**

Sebastian Frericks, Director Investor Relations, Carl Zeiss Meditec AG  
Tel. +49 3641 220-116, E-Mail: [investors.meditec@zeiss.com](mailto:investors.meditec@zeiss.com)

### **Press contact**

Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss Meditec AG  
Tel. +49 3641 220-331, E-Mail: [press.meditec@zeiss.com](mailto:press.meditec@zeiss.com)

#### **Carl Zeiss Meditec AG**

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on TecDax of the German stock exchange, is one of the world's leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumables. The company creates innovative visualization solutions in the field of microsurgery. The company's medical technology portfolio is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy.

In fiscal year 2013/14 (ended 30 Sept) the around 3,000 employees of the Carl Zeiss Meditec Group generated revenue of EUR 909 million.

The company headquarters are located in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research in India (CARIn) in Bangalore, India, and the ZEISS Innovation Center for Research and Development in Shanghai, China, strengthen the company's presence in these fast-growing countries. Around 35 percent of Carl Zeiss Meditec AG shares are in free float. The remaining approx. 65% are held by Carl Zeiss AG, one of the world's leading companies in the optical and optoelectronic industries.

For more information visit our website at:  
[www.zeiss.com/meditec-ag/en\\_de/home](http://www.zeiss.com/meditec-ag/en_de/home)